Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $50.7 million.

  • Viridian Therapeutics, Inc.\DE's Total Current Liabilities rose 2256.07% to $50.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.7 million, marking a year-over-year increase of 2256.07%. This contributed to the annual value of $47.9 million for FY2024, which is 7974.09% up from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Total Current Liabilities is $50.7 million, which was up 2256.07% from $52.6 million recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Total Current Liabilities peaked at $52.6 million during Q2 2025, and registered a low of $13.6 million during Q4 2021.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's median Total Current Liabilities value was $26.6 million (recorded in 2023), while the average stood at $29.1 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 15033.47% in 2021, then crashed by 2013.25% in 2023.
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Total Current Liabilities stood at $13.6 million in 2021, then skyrocketed by 144.57% to $33.3 million in 2022, then fell by 20.13% to $26.6 million in 2023, then surged by 79.74% to $47.9 million in 2024, then increased by 5.89% to $50.7 million in 2025.
  • Its last three reported values are $50.7 million in Q3 2025, $52.6 million for Q2 2025, and $33.7 million during Q1 2025.